ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,288 | +13.3% | 2,126 | +104.0% | 0.00% | – |
| Q2 2023 | $9,964 | +38.4% | 1,042 | +62.3% | 0.00% | – |
| Q1 2023 | $7,199 | -10.0% | 642 | +18.5% | 0.00% | – |
| Q4 2022 | $8,000 | -11.1% | 542 | +18.6% | 0.00% | – |
| Q3 2022 | $9,000 | -18.2% | 457 | 0.0% | 0.00% | – |
| Q2 2022 | $11,000 | +37.5% | 457 | +14.2% | 0.00% | – |
| Q1 2022 | $8,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | -55.6% | 400 | -45.2% | 0.00% | – |
| Q3 2021 | $18,000 | -76.0% | 730 | -73.6% | 0.00% | – |
| Q2 2021 | $75,000 | +257.1% | 2,764 | +291.5% | 0.00% | – |
| Q1 2021 | $21,000 | -93.8% | 706 | -94.1% | 0.00% | -100.0% |
| Q4 2020 | $336,000 | +2700.0% | 11,961 | +2890.2% | 0.00% | – |
| Q3 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q1 2020 | $12,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |